Update on Quinolone-containing Rescue Therapies for Infection

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2020 May 1

PMID 32351290

Citations 8

Authors

Hideki Mori

Hidekazu Suzuki

Affiliations

Soon will be listed here.

Abstract

Third generation of quinolones, such as levofloxacin and moxifloxacin, -containing regimens are often used in second-line or rescue treatment of infection. However, the increasing antibiotic resistance to quinolones affects the efficacies of quinolones-containing therapies in recent years. Therefore, there is a need to enhance the effectiveness of quinolones-containing therapies. Sitafloxacin, a fourth-generation quinolone, and vonoprazan, a novel potassium-competitive acid blocker, are now available as more effective treatment options. The aim of this paper is to summarize the current evidence of quinolone-containing therapies in rescue treatments, and to discuss the importance of drug sensitivity tests or analysis of mutation before treatments.

Citing Articles

Should Metronidazole Be Included in Second-Line Treatment After Standard Triple Therapy for Helicobacter pylori?: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Mori H, Nishizawa T, Morioka K, Kato M, Kanai T Helicobacter. 2025; 30(1):e70010.

PMID: 39868753 PMC: 11771550. DOI: 10.1111/hel.70010.

Amoxicillin, gemifloxacin and rabeprazole, as first-line Helicobacter pylori therapy in clinical practice: A pilot study.

Kilic G, Kilic G, Ozkahraman A, Konur S, Dertli R, Kayar Y Medicine (Baltimore). 2024; 103(18):e38012.

PMID: 38701320 PMC: 11062647. DOI: 10.1097/MD.0000000000038012.

Third-line and rescue therapy for refractory infection: A systematic review.

de Moraes Andrade P, Monteiro Y, Chehter E World J Gastroenterol. 2023; 29(2):390-409.

PMID: 36687120 PMC: 9846933. DOI: 10.3748/wjg.v29.i2.390.

Primary Antibiotic Resistance of in Different Regions of China: A Systematic Review and Meta-Analysis.

Chen J, Li P, Huang Y, Guo Y, Ding Z, Lu H Pathogens. 2022; 11(7).

PMID: 35890031 PMC: 9316315. DOI: 10.3390/pathogens11070786.

Therapeutic Potential of Sitafloxacin as a New Drug Candidate for Eradication in Korea: An In Vitro Culture-Based Study.

Choi Y, Lee S, Chung J, Kim K, Kwon K, Kim Y Antibiotics (Basel). 2021; 10(10).

PMID: 34680822 PMC: 8532961. DOI: 10.3390/antibiotics10101242.

References

Hwang J, Lee D, Lee A, Yoon H, Shin C, Park Y . Efficacy of 14-d vs 7-d moxifloxacin-based triple regimens for second-line Helicobacter pylori eradication. World J Gastroenterol. 2015; 21(18):5568-74. PMC: 4427680. DOI: 10.3748/wjg.v21.i18.5568. View

Lim J, Lee D, Lee S, Kim N, Park Y, Shin C . Moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure for Helicobacter pylori infection. World J Gastroenterol. 2015; 21(46):13124-31. PMC: 4674731. DOI: 10.3748/wjg.v21.i46.13124. View

Chuah S, Hsu P, Chang K, Chiu Y, Wu K, Chou Y . Randomized comparison of two non-bismuth-containing second-line rescue therapies for Helicobacter pylori. Helicobacter. 2012; 17(3):216-23. DOI: 10.1111/j.1523-5378.2012.00937.x. View

Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M . Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016; 65(9):1439-46. PMC: 5036253. DOI: 10.1136/gutjnl-2015-311304. View

Li B, Threapleton D, Wang J, Xu J, Yuan J, Zhang C . Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis. BMJ. 2015; 351:h4052. PMC: 4541168. DOI: 10.1136/bmj.h4052. View

Suzuki H, Nishizawa T, Tsugawa H, Hibi T . Molecular approaches and modern clinical strategies for the management of Helicobacter pylori infection in Japan. Keio J Med. 2013; 61(4):109-19. DOI: 10.2302/kjm.2012-0001-re. View

Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M . Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001; 345(11):784-9. DOI: 10.1056/NEJMoa001999. View

Suzuki H, Mori H . Helicobacter pylori: Helicobacter pylori gastritis--a novel distinct disease entity. Nat Rev Gastroenterol Hepatol. 2015; 12(10):556-7. DOI: 10.1038/nrgastro.2015.158. View

Matsuzaki J, Tsugawa H, Kashiwazaki Y, Mori H, Yamamoto Y, Kameyama H . Neutrophil-activating Protein Polymorphism of Helicobacter pylori Determines the Host Risk of Dyspepsia. Cell Mol Gastroenterol Hepatol. 2019; 8(2):295-297.e6. PMC: 6718361. DOI: 10.1016/j.jcmgh.2019.05.004. View

10.

Miehlke S, Krasz S, Schneider-Brachert W, Kuhlisch E, Berning M, Madisch A . Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of Helicobacter pylori infection. Helicobacter. 2011; 16(6):420-6. DOI: 10.1111/j.1523-5378.2011.00867.x. View

11.

Hanafiah A, Binmaeil H, Ali R, Mohamed Rose I, Lopes B . Molecular characterization and prevalence of antibiotic resistance in isolates in Kuala Lumpur, Malaysia. Infect Drug Resist. 2019; 12:3051-3061. PMC: 6774992. DOI: 10.2147/IDR.S219069. View

12.

Gisbert J, Romano M, Gravina A, Solis-Munoz P, Bermejo F, Molina-Infante J . Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments. Aliment Pharmacol Ther. 2015; 41(8):768-75. DOI: 10.1111/apt.13128. View

13.

Murakami K, Okimoto T, Kodama M, Tanahashi J, Fujioka T, Ikeda F . Sitafloxacin activity against Helicobacter pylori isolates, including those with gyrA mutations. Antimicrob Agents Chemother. 2009; 53(7):3097-9. PMC: 2704646. DOI: 10.1128/AAC.01552-08. View

14.

Nista E, Candelli M, Cremonini F, Cazzato I, Di Caro S, Gabrielli M . Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. Aliment Pharmacol Ther. 2003; 18(6):627-33. DOI: 10.1046/j.1365-2036.2003.01676.x. View

15.

Fallone C, Chiba N, Veldhuyzen Van Zanten S, Fischbach L, Gisbert J, Hunt R . The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. Gastroenterology. 2016; 151(1):51-69.e14. DOI: 10.1053/j.gastro.2016.04.006. View

16.

Hsu P, Tsai F, Kao S, Hsu W, Cheng J, Peng N . Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled.... Am J Gastroenterol. 2017; 112(9):1374-1381. DOI: 10.1038/ajg.2017.195. View

17.

Mori H, Suzuki H, Matsuzaki J, Tsugawa H, Fukuhara S, Miyoshi S . Efficacy of 10-day Sitafloxacin-Containing Third-Line Rescue Therapies for Helicobacter pylori Strains Containing the gyrA Mutation. Helicobacter. 2015; 21(4):286-94. DOI: 10.1111/hel.12286. View

18.

Wong W, Gu Q, Lam S, Fung F, Lai K, Hu W . Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection. Aliment Pharmacol Ther. 2003; 17(4):553-60. DOI: 10.1046/j.1365-2036.2003.01459.x. View

19.

Matsuzaki J, Suzuki H, Nishizawa T, Hirata K, Tsugawa H, Saito Y . Efficacy of sitafloxacin-based rescue therapy for Helicobacter pylori after failures of first- and second-line therapies. Antimicrob Agents Chemother. 2011; 56(3):1643-5. PMC: 3294878. DOI: 10.1128/AAC.05941-11. View

20.

Eisig J, Silva F, Barbuti R, Navarro-Rodriguez T, Moraes-Filho J, Pedrazzoli Jr J . Helicobacter pylori antibiotic resistance in Brazil: clarithromycin is still a good option. Arq Gastroenterol. 2011; 48(4):261-4. DOI: 10.1590/s0004-28032011000400008. View